GET DAILY SIGNALSHorizon Kinetics Medical ETF (MEDX) Gains +10.4% Over 30 Days as Pharma Holdings Drive the Advance
Key Takeaways
- MEDX climbed roughly 10.4% over the last 30 days, rising from about $34.66 to $38.25 per share.
- Over the past quarter the fund advanced about 9%, with most of the gain concentrated in October's rebound.
- The actively managed fund is heavily weighted in large-cap pharmaceuticals and biotech, with Eli Lilly alone representing roughly 20% of assets.
- Strength in LLY and the broader large-cap pharma complex was the primary driver of recent gains.
- A defensive rotation into healthcare and improving sentiment around innovative, patent-protected therapeutics supported the advance.
- With roughly 35 holdings and a 0.85% expense ratio, MEDX offers concentrated, active exposure distinct from broad healthcare index funds.
Getting to Know the Horizon Kinetics Medical ETF (MEDX) and Its Focus
The Horizon Kinetics Medical ETF is an actively managed exchange-traded fund that seeks long-term growth of capital by investing primarily in patented, first-line pharmaceuticals and biologics. These products tend to carry high profit margins and significant barriers to entry, and the fund targets companies with strong return potential, transparent clinical pipelines, and durable competitive positioning. The strategy employs a long-term perspective aimed at capturing both intrinsic valuation realization and scientific discovery.
The fund holds roughly 35 positions and is notably concentrated, with its top ten holdings accounting for more than 70% of assets. Eli Lilly is the largest position at approximately 20%, followed by AbbVie at roughly 10%, with additional weightings in Novartis, Johnson & Johnson, Amgen, Alkermes, AstraZeneca, Merck, and Bristol-Myers Squibb. Sector exposure is overwhelmingly focused on pharmaceuticals and biotechnology (more than 95% of the portfolio), with a modest cash allocation. Geographically, the fund is primarily US-listed but maintains meaningful exposure to European pharma names. The fund carries a 0.85% expense ratio and roughly $17 million in assets under management (AUM). Because it is actively managed rather than index-based, and because a single name represents about one-fifth of the portfolio, MEDX's returns can diverge sharply from broad healthcare benchmarks. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.
MEDX Price Performance: The Last 30 Days Compared to the Quarter
Over the last 30 days, MEDX rose approximately 10.4%, advancing from a closing level near $34.66 to roughly $38.25. The move was not linear: the fund pulled back through much of September, bottomed in early October, and then rallied sharply over the second half of the month. This back-half-loaded advance reflects a clear trend shift rather than a steady, gradual grind higher.
Measured over the full quarter, the gain is more modest at about 9%, from roughly $35.04 to $38.25. The contrast between the two figures underscores that the bulk of the fund's recent appreciation occurred within a short window during October, following a period of range-bound, choppy trading earlier in the period.
Factors Behind the Recent 30-Day Move in MEDX
The most important contributor to the recent move was the rebound in large-cap pharmaceuticals, led by Eli Lilly. As MEDX's dominant holding at roughly 20% of assets, LLY exerts outsized influence on the fund's daily performance, and renewed strength in that name translated directly into fund gains. Supporting positions such as ABBV, JNJ, AMGN, and MRK also contributed to the advance.
Broader market conditions reinforced the move. A rotation toward defensive, cash-generative healthcare names helped lift the pharma complex, while improving sentiment around innovative, patent-protected therapeutics and the GLP-1 obesity franchise supported the sector. Because the fund is concentrated in a handful of large positions, this sector strength was amplified relative to a more diversified healthcare fund.
Understanding the Quarterly Performance Path for MEDX
The three-month picture is best understood as a story of consolidation followed by re-rating. Through July and September, the fund traded in a relatively narrow, range-bound pattern, with large-cap pharma names lagging as investors weighed interest-rate expectations and sector rotation dynamics. The fund's low beta—historically below 0.5 relative to the S&P 500—meant it was relatively insulated from the volatility in the broader equity market during this stretch.
The October rally marked a decisive shift. Institutional flows back into healthcare and pharmaceuticals, combined with renewed enthusiasm for the fund's heavyweight holdings, drove the rebound. Over the full quarter, the roughly 9% gain reflects this late-period surge rather than a sustained, evenly distributed uptrend, highlighting how quickly sentiment in the large-cap pharma complex can turn.
Key Themes to Monitor for MEDX Going Forward
Looking ahead, several themes are likely to shape MEDX's trajectory. The performance of Eli Lilly, given its roughly 20% weighting, will remain a central variable, with the GLP-1 franchise and broader pipeline execution among the key swing factors. Regulatory and drug-pricing policy developments in the US and Europe also carry meaningful implications for the profitability of large pharma holdings.
The interest-rate environment remains relevant, as long-duration biotech valuations are sensitive to shifts in discount rates. Inflation trends and the pace of monetary policy adjustment will influence both sector rotation and the relative appeal of defensive healthcare equities. Additionally, M&A activity within pharmaceuticals and biotech, clinical-trial outcomes, and capital flows into actively managed healthcare funds could all act as catalysts or risks. Investors should monitor earnings cycles across the fund's largest holdings and any changes in sector leadership, while remaining mindful of the concentration risk inherent in a portfolio where a single name represents one-fifth of assets. From what I see, this concentration makes ongoing monitoring essential.
Exploring Tickeron’s AI Screener for ETF Analysis
I often rely on Tickeron’s AI Screener when researching concentrated funds like MEDX or comparing them to peers in healthcare. It lets me scan for technical indicators, fundamentals, and performance patterns across thousands of securities, which helps surface ideas that match specific criteria without manual effort. In my view, this kind of tool streamlines the process of evaluating drivers behind moves like the recent pharma rebound and spotting comparable opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MEDX's RSI Indicator is staying in overbought zone for 1 day
Watch for a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
MEDX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MEDX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on MEDX as a result. In 48 of 61 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for MEDX just turned positive on October 12, 2026. Looking at past instances where MEDX's MACD turned positive, the stock continued to rise in 28 of 32 cases over the following month. The odds of a continued upward trend are 88%.
MEDX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MEDX crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDX advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement